Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Search

Top

ACEA BIOSCIENCES INC.6779 MESA RIDGE ROAD, SUITE 100SAN DIEGOCA921211310

UEI: SLED_6F0A0A6A883FB3E8

ACEA BIOSCIENCES INC.6779 MESA RIDGE ROAD, SUITE 100SAN DIEGOCA921211310 is a federal contractor, registered under UEI SLED_6F0A0A6A883FB3E8. It has been awarded $4,947,000 across 1 federal contract. Primary work spans Research and Development in Biotechnology. Top awarding agencies include Information Technology Acq Division (ita.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_6F0A0A6A883FB3E8

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Information Technology Acq Division (ita$4.9M100%

Awards by NAICS

541711 - Research and Development in Biotechnology$4.9M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in ACEA BIOSCIENCES INC.6779 MESA RIDGE ROAD, SUITE 100SAN DIEGOCA921211310's top NAICS codes and agencies

Biosafety & Recombinant DNA Research ComplianceThe U.S. Air Force, under the U.S. Department of Defense, is seeking a subcontract for Biosafety and Recombinant DNA Research Compliance. The primary objective of this engagement is to ensure strict adherence to federal biosafety regulations and to provide necessary support for Institutional Biosafety Committee approval regarding research involving recombinant DNA molecules. This opportunity is designated as a Total Small Business Set-Aside under the SBIR/STTR mandate for companies with fewer than 500 employees, falling under NAICS code 541711. The solicitation was posted on August 26, 2026, with a response deadline of September 9, 2026, at 4:00 PM.

POSTED

DEADLINE

Technical R&D Execution in Specialized DomainsThe U.S. Air Force, under the Department of Defense, is seeking a subcontractor to perform applied research and development within specialized technical domains, including artificial intelligence, machine learning, biotechnology, materials science, and unmanned systems. This effort is conducted under Phase I Small Business Innovation Research awards to advance critical technological capabilities. This opportunity is a total small business set-aside, requiring participants to have fewer than 500 employees to comply with SBIR/STTR mandates. The solicitation was posted on August 26, 2026, with a response deadline of September 9, 2026. The work falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences.

POSTED

DEADLINE

Novel In-Situ Binder Chemistry Development

NASA SBIR/STTR Program

POSTED

DEADLINE

Candidate Influenza Vaccine Virus (CVV) Development

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Data Collection & Analytics for Lunar MissionsThe National Aeronautics And Space Administration, specifically the Space Operations Mission Directorate, is seeking a subcontractor to develop data collection frameworks and analytical models focused on health metrics. This initiative is designed to monitor and analyze astronaut health during lunar missions ranging from short-duration stays to month-long deployments. The opportunity was posted on August 11, 2026, with a response deadline of September 8, 2026. Classified under NAICS code 541711, the project emphasizes the creation of robust systems to ensure the well-being of crew members during extended lunar operations.

Space Operations Mission Directorate

POSTED

DEADLINE

Pharmaceutical-Based Agent (PBA) Detection Systems

POSTED

DEADLINE

Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

in about 2 months

Phage-Based Formulation Development

W6QK Acc Ccdc Sttc

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

DEADLINE

Nanobody-Drug Conjugate Systems DevelopmentThe contract pertains to the licensing of the NanoFET platform to develop targeted nanobody-drug conjugates for the precision delivery of therapeutics using a modular scaffold designed to enhance specificity and efficiency in therapeutic distribution. This subcontract, issued by the Department of Energy through its contractor Triad, enables the recipient to leverage the proprietary NanoFET technology for advancing next-generation drug delivery systems with a focus on oncology and other targeted disease treatments. The project is centered in Los Alamos, New Mexico, with a response deadline of December 18, 2026, and falls under the NAICS code 541711 for research and development in biotechnology. The modular scaffold allows for customizable conjugation of nanobodies with therapeutic payloads, facilitating high-affinity targeting of disease markers while minimizing off-target effects. The agreement emphasizes technological innovation and the translation of advanced nanoscale platforms into clinically viable delivery systems.

Triad - DOE Contractor

POSTED

DEADLINE

Infectious Disease Vaccine DevelopmentThe contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.

Triad - DOE Contractor

POSTED

DEADLINE

Modular Cancer Immunotherapy DevelopmentThe contract entails the license and development of the NanoFET platform for the creation of targeted cancer immunotherapies, leveraging its modular scaffold to deliver tumor-specific antigens and immune stimulators in a precise and effective manner. The work is focused on advancing next-generation immunotherapeutic approaches by engineering the platform to enhance immune recognition and response against cancer cells, with the goal of improving therapeutic outcomes and reducing off-target effects. The project requires collaboration to optimize the platform’s design, validate its efficacy in preclinical models, and prepare for subsequent clinical translation, all grounded in cutting-edge nanotechnology and immunological science. The contract is a subcontract under the Department of Energy, with performance centered in Los Alamos, New Mexico, 87545, and is classified under NAICS code 541711 for research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, with a response deadline of December 18, 2026, indicating a strategic timeline for proposal submission and evaluation. While details on set-aside status and point of contact are not provided, the project is positioned to align with national priorities in advanced biomedical innovation and cancer treatment, leveraging federal research infrastructure and expertise to drive transformative therapeutic solutions.

Triad - DOE Contractor

POSTED

DEADLINE

Antibody Development & LicensingThe contract involves the development, validation, and commercialization of monoclonal antibodies that specifically target bacterial membrane lipids. This work utilizes a nanodisc platform, which serves either as an immunogen or a screening tool, to enhance the effectiveness of antibody generation and assessment. The effort is positioned as a subcontract under the Department of Energy's Triad contractor, emphasizing a focus on innovative biotechnological approaches within a government research context. Work will be performed in Los Alamos, with the solicitation posted in mid-2026 and a response deadline toward the end of that year. The contract falls under NAICS code 541711, indicating its alignment with research and development in the physical, engineering, and life sciences. Although specific organizational and contact details are not provided, the contract is geared toward advancing antibody technologies through a combination of advanced immunological platforms and commercial application strategies.

Triad - DOE Contractor

POSTED

DEADLINE